Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE16
|
| gptkbp:CASNumber |
877399-52-5
|
| gptkbp:chemicalFormula |
C21H22Cl2FN5O
|
| gptkbp:genericName |
gptkb:crizotinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xalkori
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
ROS1-positive metastatic non-small cell lung cancer |
| gptkbp:KEGGID |
D09722
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1173476
gptkb:DB08865 11626560 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema vision disorder |
| gptkbp:synonym |
gptkb:PF-02341066
|
| gptkbp:target |
gptkb:ALK
ROS1 |
| gptkbp:UNII |
A83GS77B8T
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:crizotinib
|
| gptkbp:bfsLayer |
6
|